← Eichor
Study identifier: NCT07124299 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Alpha-Blockers Prior to Ureteral Access Sheath Placement in Flexible Ureteroscopy: A Randomized Prospective Study

Condition: Nephrolithiasis · Alpha Blocker · Ureteral Access Sheath  ·  Sponsor: Pedro de Figueiredo Buchalla

PhasePhase 4
Planned participants140
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to evaluate whether the use of alpha-blockers before flexible ureterorenolithotripsy facilitates the passage of the ureteral access sheath. The trial will enroll adult patients diagnosed with kidney stones who are scheduled for flexible ureteroscopy. Participants will be randomly assigned to receive or not receive alpha-blockers for seven days before surgery. The primary outcome is the rate of successful sheath placement without the need for a second procedure. Secondary outcomes include the incidence of ureteral injuries and the need for additional surgical interventions. The goal is to improve surgical efficiency and patient outcomes in the treatment of kidney stones.

This description comes directly from the study's public registry record.

Talk to the study team

Pedro FB Buchalla, MD  ·  +5516997704207  ·  pedrofbuchalla@gmail.com

Always discuss trial participation with your own doctor first.

Locations (1)

Centro Universitário FMABCSanto André, São Paulo, BrazilRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07124299